Antiproliferative and proapoptotic activities of new pyrazolo[3,4‐ d ]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most frequent primitive malignant tumor of the skeletal system, char acterized by an extremely aggressive clinical course that still lacks an effective treatment. Src kinase seems to be involved in the osteosarcoma malignant phenotype. We show that the treatment of human osteosarcoma cell lines with a new pyrazolo[3,4‐d]pyrimidine derivative Src inhibitor, namely SI‐83, impaired cell viability, with a half‐maximal inhibitory concentration of 12 μ.M in nonstarved cells and a kinetic different from that known for the Src inhibitor PP2. Analysis by terminal deoxynucleotidyl transferase‐mediated nick end labeling, Hoechst, and flow cytometric assay showed that SI‐83 induced apoptosis in SaOS‐2 cells. Moreover, SI‐83, by inhibiting Src phosphorylation, decreased in vivo osteosarcoma tumor mass in a mouse model. Finally, SI‐83 showed selectivity for osteosarcoma, since it had a far lower effect in primary human osteoblasts. These results show that human osteosarcoma had Src‐ dependent proliferation and that modulation of Src activity may be a therapeutic target of this new com pound with low toxicity for nonneoplastic cells—Spreafico, A., Schenone, S., Serchi, T., Orlandini, M., Angelucci, A., Magrini, D., Bernardini, G., Collodel, G., Di Stefano, A., Tintori, C., Bologna, M., Manetti, F., Botta, M., Santucci, A. Antiproliferative and proapo‐ ptotic activities of new pyrazolo[3,4‐d]pyrimidine deriv ative Src kinase inhibitors in human osteosarcoma cells. FASEBJ. 22, 1560–1571 (2008)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Cited by
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Medicinal attributes of pyrazolo[3,4-d]pyrimidines: A review
Chauhan, M., & Kumar, R. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.07.027 · Cited by 168
Yang, C., Lu, P., Lee, F. Y., Chadburn, A., Barrientos, J. C., Leonard, J. P., Ye, F., Zhang, D., Knowles, D. M., & Wang, Y. L. (2008) · Leukemia · doi:10.1038/leu.2008.163 · Cited by 61
Jensen, H. A., Styskal, L. E., Tasseff, R., Bunaciu, R. P., Congleton, J., Varner, J. D., & Yen, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058621 · Cited by 18
“PP2 has previously been shown to reduce proliferation in myeloid blasts [46], and other cell types [43,47].”
Background
Metadata
- Authors
- Spreafico, A., Schenone, S., Serchi, T., Orlandini, M., Angelucci, A., Magrini, D., Bernardini, G., Collodel, G., Di Stefano, A., Tintori, C., Bologna, M., Manetti, F., Botta, M., & Santucci, A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2008-01-02
- Volume
- 22
- Issue
- 5
- Pages
- 1560-1571
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2155398859
- Cited by
- 63
- References
- 1
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiproliferative and proapoptotic activities of new pyrazolo[3,4‐ d ]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. https://app.cochat.ai/papers/10.1096/fj.07-9873com
- The paper
- Spreafico, A., Schenone, S., Serchi, T., Orlandini, M., Angelucci, A., Magrini, D., Bernardini, G., Collodel, G., Di Stefano, A., Tintori, C., Bologna, M., Manetti, F., Botta, M., & Santucci, A. (2008). Antiproliferative and proapoptotic activities of new pyrazolo[3,4‐ d ]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. The FASEB Journal. https://doi.org/10.1096/fj.07-9873com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.